| SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus M Dogan, L Kozhaya, L Placek, C Gunter, M Yigit, R Hardy, M Plassmeyer, ... Communications Biology 4 (1), 129, 2021 | 101 | 2021 |
| Reproducibility of Fluorescent Expression from Engineered Biological Constructs in E. coli J Beal, T Haddock-Angelli, M Gershater, K De Mora, M Lizarazo, ... PloS one 11 (3), e0150182, 2016 | 54 | 2016 |
| A distal enhancer at risk locus 11q13.5 promotes suppression of colitis by Treg cells R Nasrallah, CJ Imianowski, L Bossini-Castillo, FM Grant, M Dogan, ... Nature 583 (7816), 447-452, 2020 | 48 | 2020 |
| Antibody responses to SARS-CoV-2 after infection or vaccination in children and young adults with inflammatory bowel disease J Dailey, L Kozhaya, M Dogan, D Hopkins, B Lapin, K Herbst, ... Inflammatory bowel diseases 28 (7), 1019-1026, 2022 | 45 | 2022 |
| Functional interrogation of primary human T cells via CRISPR genetic editing X Chen, L Kozhaya, C Tastan, L Placek, M Dogan, M Horne, R Abblett, ... The Journal of Immunology 201 (5), 1586-1598, 2018 | 43 | 2018 |
| Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19 M Dogan, L Kozhaya, L Placek, CL Gunter, M Yigit, R Hardy, ... MedRxiv, 2020.07. 07.20148106, 2020 | 35 | 2020 |
| Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy M Dogan, E Karhan, L Kozhaya, L Placek, X Chen, M Yigit, D Unutmaz The Journal of Immunology 209 (8), 1523-1531, 2022 | 20 | 2022 |
| Chemotherapeutics and CAR‐T cell‐based immunotherapeutics screening on a 3D bioprinted vascularized breast tumor model M Dey, MH Kim, M Dogan, M Nagamine, L Kozhaya, N Celik, D Unutmaz, ... Advanced Functional Materials 32 (52), 2203966, 2022 | 18 | 2022 |
| Biofabrication of 3D breast cancer models for dissecting the cytotoxic response of human T cells expressing engineered MAIT cell receptors M Dey, MH Kim, M Nagamine, E Karhan, L Kozhaya, M Dogan, ... Biofabrication 14 (4), 044105, 2022 | 14 | 2022 |
| Targeting SARS‐CoV‐2 infection through CAR‐T‐like bispecific T cell engagers incorporating ACE2 M Dogan, L Kozhaya, L Placek, F Karabacak, M Yigit, D Unutmaz Clinical & Translational Immunology 11 (10), e1421, 2022 | 6 | 2022 |
| Chemotherapeutics and CAR‐T Cell‐Based Immunotherapeutics Screening on a 3D Bioprinted Vascularized Breast Tumor Model (Adv. Funct. Mater. 52/2022). M Dey, MH Kim, M Dogan, M Nagamine, L Kozhaya, N Celik, D Unutmaz, ... Advanced Functional Materials 32 (52), 2022 | 2 | 2022 |
| 3D Bioprinted perfusable and vascularized breast tumor model for dynamic screening of chemotherapeutics and CAR-T cells M Dey, MH Kim, M Nagamine, M Dogan, L Kozhaya, D Unutmaz, ... BioRxiv, 2022.03. 15.484485, 2022 | 2 | 2022 |
| 731 Failure to develop neutralizing antibodies following SARS-COV-2 infection in young patients with inflammatory bowel disease receiving biologics J Dailey, JS Hyams, D Hopkins, K Grandonico, M Brimacombe, B Lapin, ... Gastroenterology 160 (6), S-146, 2021 | 1 | 2021 |
| The role of ADAMTS9 gene promoter (Ca) repeat in developmental hip dysplasia AE Yilmaz, H Atalar, M Acar, M Dogan, MN Aytekin, M Gunduz, E Gunduz Clinical and Investigative Medicine (Online) 38 (4), E213, 2015 | 1 | 2015 |
| STAT4 Phosphorylation of T-helper Cells predicts surgical outcomes in Refractory Chronic Rhinosinusitis MR Abidin, O Alpan, M Plassmeyer, L Kozhaya, D Loizou, M Dogan, ... medRxiv, 2023 | | 2023 |
| Sars-cov-2 therapies M Dogan, D Unutmaz US Patent App. 18/182,934, 2023 | | 2023 |
| Engineering human Mucosal Associated Invariant T (MAIT) cells with chimeric antigen receptors for cancer immunotherapy1 M Dogan, E Karhan, L Kozhaya, L Placek, X Chen, M Yigit, D Unutmaz bioRxiv, 2022.07. 28.501764, 2022 | | 2022 |
| Development of 3D breast cancer models with human T cells expressing engineered MAIT cell receptors M Dey, MH Kim, M Nagamine, E Karhan, L Kozhaya, M Dogan, ... bioRxiv, 2022.01. 29.478309, 2022 | | 2022 |
| Targeting SARS-CoV-2 infection through CAR T cells and bispecific T cell engagers M Dogan, L Kozhaya, L Placek, F Karabacak, M Yigit, D Unutmaz bioRxiv, 2022 | | 2022 |
| Targeting SARS-CoV-2 infection through CAR T cells and bispecific T cell engagers (preprint) M Dogan, L Kozhaya, L Placek, F Karabacak, M Yigit, D Unutmaz | | 2022 |
